

## CA-17112: PROSPECTIVE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK

### 3<sup>rd</sup> TRAINING SCHOOL: Discovery to translation

11-12 OCTOBER 2021. NOTTINGHAM, UK

The course will be held in a hybrid-mode, with both in-person and virtual lectures (zoom platform). Nevertheless, the attendance in person is highly encouraged, if the circumstances allow.

**Course Coordinator: Guruprasad P Aithal**

**Teaching Staff:** The teaching staff is composed by lecturers with expertise in the field of each seminar. As such it includes professionals from academia and regulatory sciences, including CA 17-112 members and invited external experts.

**Participants:** This course targets all PhD students, young investigators, and scientific community members.

**Short introduction:** Important advances have been made in the understanding of the complexities of Drug-Induced Liver Injury. It is our commitment to translate that knowledge to improve liver safety in drug development and clinical practice. Similarly, emerging topics and potentially future developments that have been identified during the Action CA17112 and are in need of further research would be addressed.

These activities would enable harmonization of basic and clinical research across Europe and provide a roadmap for DILI research and treatment in Europe for the coming decade.

#### **Goals and Learning Outcomes:**

The goal is to bring about a fundamental change in the way drug hepatic safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice

Outcomes:

To present creative free tools in order to improve safety monitoring

To highlight the new Frontiers in Drug-induced Liver Injury

ECIs personal growth and scientific enrichment. To grow ECIs leadership skills and preparing them to be actively involved in future cross-border multi-centre, multi-disciplinary studies

**Registration:** Spots are limited to 8 trainees

**Deadline for applications:** 4<sup>th</sup> October 2021

### **Application:**

Those trainees who want to apply for a COST reimbursement, and based on the COST rules for Training School, should send the following documents:

- a) Cover letter, briefly (max. 2 pages) introducing the applicant, with information about the affiliation, academic and research background, interest in the TS and reasoning for attending the TS;
- b) Applicant's CV (max 2 pages), including relevant publications;
- c) Reference letter from at least one CA 17-112 member.

The submission will be made by e-mail to [lunov@fzu.cz](mailto:lunov@fzu.cz) and [gareth.sullivan@medisin.uio.no](mailto:gareth.sullivan@medisin.uio.no).

## **AGENDA**

### **October 11**

#### **3<sup>rd</sup> TRAINING SCHOOL Discovery to translation**

15.15-15.35: Check-point inhibitor induced liver injury (CHILI): EASL Registry. **Palak Trivedi, Birmingham, UK.**

15.45-16.05: Prescription event monitoring. **Edmond Atallah, Nottingham, UK.**

16.15-16.35: Computational modelling for DILI. **Minjun Chen, FDA, USA.**

16.45-17.05: **COFFEE BREAK**

17.10-17.30: DILI - a genotype to phenotype approach using patient derived stem cells. **Tamir Rashid, London, UK.**

17.40-18.00: Organoid based cholestatic DILI modelling. **Takanori Takebe, Japan and USA.**

18.10-18.30. **ROUND TABLE.**

## October 12

### **WORKSHOP / 3<sup>rd</sup> TRAINING SCHOOL Discovery to translation.**

09.00-09.20: In vivo imaging: Oxidative stress. **Stephen Bawden. Nottingham, UK**

09.30-09.50: Epigenetics: In vitro to In vivo. **Mujdat Zeybel. Istanbul, Turkey**

10.00-10.20: In vivo imaging: Oxidative stress. **Stephen Bawden. Nottingham, UK**

10.30-10.50: **COFFEE BREAK**

11.00-11.20: Quantitative proteomic profiling to laboratory essays. **Ravi Kodihalli. Pfizer,**

**USA** 11.25-11.45: Mass cytometry in DILI research. **Stuart Astbury. Nottingham, UK**

11-50- 12.10: SNS and Acute Liver repair: worth a hassle? **Jude Oben, London, UK**

12.10- 12.40: **Discussion + Wrap up**

**13.00-14.30: Lunch**